PLASMA HEPARANASE AS A SIGNIFICANT MARKER OF TREATMENT RESPONSE IN CHILDREN WITH HODGKIN LYMPHOMA: Pilot Study

REFERENCES

• Pizzo and Poplack. Principles and Practice of Pediatric Oncology, 4th, , et al. Lippincott, Philadelphia 2006
   Google Scholar
• Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Natl Med 1995; 1: 27–31
   PubMed Web of Science ®Google Scholar
• Pavlakovic H, Von Schutz V, Rossler J, et al. Quantification of angiogenesis stimulators in children with solid malignancies. Int J Cancer 2001; 92: 756–760
   PubMed Web of Science ®Google Scholar
• Tabone MD, Landman-Parker J, Arcil B. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with solid malignant tumors?. Clin Cancer Res 2001; 7: 538–543
   PubMed Web of Science ®Google Scholar
• Ben Arush M, Schenzer P, Maurice S, et al. Serum vascular endothelial growth factor as a significant marker of treatment response in pediatric malignancies. Pediatr Hematol Oncol 2005; 22: 513–524
   PubMed Web of Science ®Google Scholar
• Ben Arush M, Ben Barak A, Maurice S, et al. Serum VEGF as a significant marker of treatment response in Hodgkin lymphoma. Pediatr Hematol Oncol 2007; 24: 111–115
   PubMed Web of Science ®Google Scholar
• Dempsey LA, Brunn GJ, Platt JL. Heparanase, a potential regulator of cell–matrix interactions. Trends Biochem Sci 2000; 25: 349–351
   PubMed Web of Science ®Google Scholar
• Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001; 108: 341–347
   PubMed Web of Science ®Google Scholar
• Katz A, Van-Dijk DJ, Aingorn H, et al. Involvement of human heparanase in the pathogenesis of diabetic nephropathy. Isr Med Assoc J 2002; 4: 996–1002
   PubMed Web of Science ®Google Scholar
• Shafat I, Zcharia E, Nisman B, et al. An ELISA method for the detection and quantification of human heparanase. Biochem Biophys Res Commun 2006; 341: 958–963
   PubMed Web of Science ®Google Scholar
• Nardella C, Steinkuhler C. Radiolabeled heparan sulfate immobilized on microplate as substrate for the detection of heparanase activity. Anal Biochem 2004; 232: 368–375
   Google Scholar
• Donaldson SS, Hudson MM, Lamborn KR, et al. VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial. J Clin Oncol 2002; 20: 3081–3087
   PubMed Web of Science ®Google Scholar
• Kelly KM, Hutchinson RJ, Sposto R, et al. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704. Ann Oncol 2002; 13(Suppl 1)107–111
   Google Scholar
• Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386–2395
   PubMed Web of Science ®Google Scholar
• Vlodavsky I, Schirrmacher V, Ariav Y, Fuks Z. Lymphoma cell-mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relationship to tumor cell metastasis. Cancer Res 1983; 43: 2704–2711
   PubMed Web of Science ®Google Scholar
• Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006; 38: 2018–2039
   PubMed Web of Science ®Google Scholar
• Vlodavsky I, Abboud Jarrous G, Elkin M. The impact of heparanase and heparin on cancer metastasis and angiogenesis. Pathophysiol Haemost Thromb 2006; 35: 116–127
   PubMed Web of Science ®Google Scholar
• Vlodavsky I, Ilan N, Naggi A. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des 2007; 13: 2057–2073
   PubMed Web of Science ®Google Scholar
• Mainou-Fowler T, Angus B, Miller S, et al. Micro-vessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PdEGF) in classical Hodgkin lymphoma (HL). Leuk Lymphoma 2006; 47: 223–230
   PubMed Web of Science ®Google Scholar
• Doussis-Anagnostopoulou IA, Talks KL, Turley H, et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease. J Pathol 2002; 197: 677–683
   PubMed Web of Science ®Google Scholar
• Foss HD, Araujo I, Demel G, et al. Expression of vascular endothelial growth factor in lymphomas and Castleman's disease. J Pathol 1997; 183: 44–50
   PubMed Web of Science ®Google Scholar
• Agarwal B, Naresh KN, Re: Doussis-Anagnostopoulou et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease. J Pathol 2003; 201: 334–335
   PubMed Web of Science ®Google Scholar